ClinicalTrials.gg
CompletedNCT00475423Updated Feb 23, 2015Results posted

A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

A Phase 2 interventional study of rituximab [MabThera/Rituxan] in Idiopathic Thrombocytopenic Purpura, sponsored by Hoffmann-La Roche. Completed at 12 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-23.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. Rituximab · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
6th of 27
122 · median 60
Started
2007
with 1 other
Phase 2
9 of 27
none open now
Registered
6th of 27
by date
Lead sponsor
2 of 27
Hoffmann-La Roche

Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 2 that started in 2007, is one of 9 in phase 2, and was the 6th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP). Patients will receive infusions of MabThera 1000mg i.v. on days 1 and 15. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • , relapsing or chronic idiopathic thrombocytopenic purpura;
  • stable therapy during 3 weeks prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • newly diagnosed ITP (\<6 weeks);
  • prior treatment with MabThera;
  • active bleeding requiring transfusion within 7 days prior to entry into study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000mg iv on days 1 and 15

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)

    Percentage of participants with an overall response at Week 8 achieving a CR or PR as evaluated by platelets, new or increased Idiopathic Thrombocytopenic Purpura (ITP)-related treatments and corticosteroids given for Adverse Events (AEs). CR was defined as a platelet count of greater than (\>) 150x10\^9/ liters (L) over at least 2 consecutive measurements at least 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. PR was defined as platelet count of \>50x10\^9/L over at least 2 consecutive measurements at least \<2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Overall response rate (participants who achieved CR or confirmed PR) was evaluated using platelets, new or increased ITP related treatments, and corticosteroids given for AEs.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants With Hematological CR, PR, or Minor Response (MR)

    Percentage of participants with CR, PR, and MR at Week 8 as evaluated by platelet count where CR is greater than or equal to (≥)150x10\^9/L, PR ≥ 50x10\^9/L, MR equals (=) 30x10\^9/L over 2 consecutive measurements at least 2 weeks apart but no more than 60 days apart with no increase in concomitant therapy or initiation of new ITP therapy.

    Time frame: Week 8

  2. Percentage of Participants Who Achieved CR

    CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 52

  3. Time to CR

    Time to CR was defined as the time from the first infusion to the first date on which CR was achieved. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants without an event were censored at the date of last assessment.

    Time frame: Baseline to Week 52

  4. Percentage of Participants Who Achieved PR

    PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 52

  5. Time to PR

    Time to response was defined as the time from the first infusion to the first date on which PR was achieved. PR was defined as platelet counts \> 50x10\^9/L over ≥ 2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Baseline to Week 52

  6. Percentage of Participants Who Achieved MR

    MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 52

  7. Time to MR

    Time to response was defined as the time from the first infusion to the first date on which MR was achieved. MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 percent (%) to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Baseline to Week 52

  8. Percentage of Participants With Continued CR From Week 8 to Week 52

    The number of participants with a durable CR assessed in CR responders whose responses were sustained from Week 8 through to the end of the study or withdrawal, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 8 to Week 52

  9. Duration of CR in Participants With Continued CR From Week 8 Until Week 52

    Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of CR, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 8 to Week 52

  10. Duration of PR in Participants With Continued PR From Week 8 Until Week 52

    Duration of PR was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of PR, irrespective of change of treatment. PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 8 to Week 52

  11. Duration of MR in Participants With Continued MR From Week 8 Until Week 52

    Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of MR, irrespective of change of treatment. MR was defined as participants registered with ITP in relapse with a platelet count of \> 30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50% to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

    Time frame: Week 8 to Week 52

  12. Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event

    Percentage of participants with an event of initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.

    Time frame: Week 52

  13. Time to Initiation of New ITP Therapy

    Median time in days to initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.

    Time frame: Baseline to Week 52

  14. Percentage of Therapeutic Responders

    Percentage of participants with a therapeutic response, defined as achieving CR, PR, or MR assessed at Week 26 and Week 52 or hematological response, defined as achieving CR, PR, or MR at Week 8. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR response was defined as at least a minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least a minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.

    Time frame: Week 26 and Week 52

  15. Percentage of Participants With a Therapeutic Response

    Number of therapeutic responder participants by CR, PR, MR, or no response (NR) measured at Week 26 and Week 52. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR was defined as at least minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.

    Time frame: Week 26 and Week 52

  16. Cluster of Differentiation 19 (CD19) B Cell Count

    Value of mean CD19+ B cell count at baseline. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.

    Time frame: Baseline, Weeks 1, 3, and 8, Follow-up Months 4, 6, 8, 10, and 12, and Last Day

  17. Change From Baseline in CD19 B Cell Count

    Actual values of CD19+ mean B cell count assessed at Weeks 3 and 8, and Months 4, 6, 8, 10 and 12, and last day. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.

    Time frame: Weeks 3, 8 and Months 4, 6, 8, 10 and 12, and last day

07

Results

Posted Feb 23, 2015

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started122
Completed90
Not completed32
Withdrew: Protocol violation5
Withdrew: Adverse event4
Withdrew: Withdrawal by subject6
Withdrew: Lack of efficacy8
Withdrew: Death1
Withdrew: Reason not specified1
Withdrew: Lost to follow-up7

Outcome measures

PrimaryPercentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)

Percentage of participants with an overall response at Week 8 achieving a CR or PR as evaluated by platelets, new or increased Idiopathic Thrombocytopenic Purpura (ITP)-related treatments and corticosteroids given for Adverse Events (AEs). CR was defined as a platelet count of greater than (\>) 150x10\^9/ liters (L) over at least 2 consecutive measurements at least 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. PR was defined as platelet count of \>50x10\^9/L over at least 2 consecutive measurements at least \<2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Overall response rate (participants who achieved CR or confirmed PR) was evaluated using platelets, new or increased ITP related treatments, and corticosteroids given for AEs.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)
percentage of participantsRituximab 1000 mg
Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)43.5 (34.0 to 53.4)
SecondaryPercentage of Participants With Hematological CR, PR, or Minor Response (MR)

Percentage of participants with CR, PR, and MR at Week 8 as evaluated by platelet count where CR is greater than or equal to (≥)150x10\^9/L, PR ≥ 50x10\^9/L, MR equals (=) 30x10\^9/L over 2 consecutive measurements at least 2 weeks apart but no more than 60 days apart with no increase in concomitant therapy or initiation of new ITP therapy.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Hematological CR, PR, or Minor Response (MR)
percentage of participantsRituximab 1000 mg
CR9.3 (4.5 to 16.4)
PR34.3 (25.4 to 44.0)
MR17.6 (10.9 to 26.1)
SecondaryPercentage of Participants Who Achieved CR

CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved CR
percentage of participantsRituximab 1000 mg
Percentage of Participants Who Achieved CR27.8
SecondaryTime to CR

Time to CR was defined as the time from the first infusion to the first date on which CR was achieved. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants without an event were censored at the date of last assessment.

Time frame:
Baseline to Week 52
Reported as:
Median · days
Time to CR
daysRituximab 1000 mg
Time to CRNA (305.0 to NA)
SecondaryPercentage of Participants Who Achieved PR

PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PR
percentage of participantsRituximab 1000 mg
Percentage of Participants Who Achieved PR56.5
SecondaryTime to PR

Time to response was defined as the time from the first infusion to the first date on which PR was achieved. PR was defined as platelet counts \> 50x10\^9/L over ≥ 2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Baseline to Week 52
Reported as:
Median · days
Time to PR
daysRituximab 1000 mg
Time to PR53.0 (36.0 to 152.0)
SecondaryPercentage of Participants Who Achieved MR

MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MR
percentage of participantsRituximab 1000 mg
Percentage of Participants Who Achieved MR71.3
SecondaryTime to MR

Time to response was defined as the time from the first infusion to the first date on which MR was achieved. MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 percent (%) to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Baseline to Week 52
Reported as:
Median · days
Time to MR
daysRituximab 1000 mg
Time to MR22.0 (8.0 to 30.0)
SecondaryPercentage of Participants With Continued CR From Week 8 to Week 52

The number of participants with a durable CR assessed in CR responders whose responses were sustained from Week 8 through to the end of the study or withdrawal, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 8 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Continued CR From Week 8 to Week 52
percentage of participantsRituximab 1000 mg
Percentage of Participants With Continued CR From Week 8 to Week 5210
SecondaryDuration of CR in Participants With Continued CR From Week 8 Until Week 52

Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of CR, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 8 to Week 52
Reported as:
Median · days
Duration of CR in Participants With Continued CR From Week 8 Until Week 52
daysRituximab 1000 mg
Duration of CR in Participants With Continued CR From Week 8 Until Week 52NA (NA to NA)
SecondaryDuration of PR in Participants With Continued PR From Week 8 Until Week 52

Duration of PR was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of PR, irrespective of change of treatment. PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 8 to Week 52
Reported as:
Median · days
Duration of PR in Participants With Continued PR From Week 8 Until Week 52
daysRituximab 1000 mg
Duration of PR in Participants With Continued PR From Week 8 Until Week 52247.0 (219.0 to NA)
SecondaryDuration of MR in Participants With Continued MR From Week 8 Until Week 52

Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of MR, irrespective of change of treatment. MR was defined as participants registered with ITP in relapse with a platelet count of \> 30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50% to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.

Time frame:
Week 8 to Week 52
Reported as:
Median · days
Duration of MR in Participants With Continued MR From Week 8 Until Week 52
daysRituximab 1000 mg
Duration of MR in Participants With Continued MR From Week 8 Until Week 52256.0 (168.0 to NA)
SecondaryTime to Inititiation of New ITP Therapy - Percentage of Participants With an Event

Percentage of participants with an event of initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event
percentage of participantsRituximab 1000 mg
Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event50.0
SecondaryTime to Initiation of New ITP Therapy

Median time in days to initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.

Time frame:
Baseline to Week 52
Reported as:
Median · days
Time to Initiation of New ITP Therapy
daysRituximab 1000 mg
Time to Initiation of New ITP Therapy314.0 (215.0 to NA)
SecondaryPercentage of Therapeutic Responders

Percentage of participants with a therapeutic response, defined as achieving CR, PR, or MR assessed at Week 26 and Week 52 or hematological response, defined as achieving CR, PR, or MR at Week 8. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR response was defined as at least a minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least a minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.

Time frame:
Week 26 and Week 52
Reported as:
Number · percentage of participants
Percentage of Therapeutic Responders
percentage of participantsRituximab 1000 mg
Week 2643.5
Week 5235.2
SecondaryPercentage of Participants With a Therapeutic Response

Number of therapeutic responder participants by CR, PR, MR, or no response (NR) measured at Week 26 and Week 52. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR was defined as at least minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.

Time frame:
Week 26 and Week 52
Reported as:
Number · percentage participants
Percentage of Participants With a Therapeutic Response
percentage participantsRituximab 1000 mg
Week 26: CR38.0 (28.8 to 47.8)
Week 26: PR5.6 (2.1 to 11.7)
Week 26: MR0.0 (0.0 to 3.4)
Week 26: NR56.5 (46.6 to 66.0)
Week 52: CR35.2 (26.2 to 45.0)
Week 52: PR0.0 (0.0 to 3.4)
Week 52: MR0.0 (0.0 to 3.4)
Week 52: NR64.8 (55.0 to 73.8)
SecondaryCluster of Differentiation 19 (CD19) B Cell Count

Value of mean CD19+ B cell count at baseline. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.

Time frame:
Baseline, Weeks 1, 3, and 8, Follow-up Months 4, 6, 8, 10, and 12, and Last Day
Reported as:
Mean · 10^9 cells/L
Cluster of Differentiation 19 (CD19) B Cell Count
10^9 cells/LRituximab 1000 mg
Baseline (n=84)0.27 ± 0.374
Week 1 (n=3)0.30 ± 0.251
Week 3 (n=96)0.01 ± 0.052
Week 8 (n=89)0.01 ± 0.033
Follow-up Month 4 (n=57)0.01 ± 0.029
Follow-up Month 6 (n=79)0.03 ± 0.041
Follow-up Month 8 (n=57)0.07 ± 0.085
Follow-up Month 10 (n=48)0.15 ± 0.315
Follow-up Month 12 (n=70)0.18 ± 0.289
Last Day (n=101)0.13 ± 0.252
SecondaryChange From Baseline in CD19 B Cell Count

Actual values of CD19+ mean B cell count assessed at Weeks 3 and 8, and Months 4, 6, 8, 10 and 12, and last day. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.

Time frame:
Weeks 3, 8 and Months 4, 6, 8, 10 and 12, and last day
Reported as:
Mean · 10^9 cells/L
Change From Baseline in CD19 B Cell Count
10^9 cells/LRituximab 1000 mg
Week 3 (n=81)-0.23 ± 0.290
Week 8 (n=75)-0.27 ± 0.393
Follow-up Month 4 (n=47)-0.21 ± 0.217
Follow-up Month 6 (n=63)-0.23 ± 0.367
Follow-up Month 8 (n=44)-0.22 ± 0.412
Follow-up Month 10 (n=39)-0.08 ± 0.207
Follow-up Month 12 (n=55)-0.06 ± 0.409
Last Day (n=84)-0.13 ± 0.389

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab 1000 mg—12/122 (9.8%)62/122 (50.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRituximab 1000 mg
AsbestosisInjury, poisoning and procedural complications1/122
Spinal Compression FractureInjury, poisoning and procedural complications1/122
Spinal FractureInjury, poisoning and procedural complications1/122
Subdural HaematomaInjury, poisoning and procedural complications1/122
Subdural HaemorrhageInjury, poisoning and procedural complications1/122
Back PainMusculoskeletal and connective tissue disorders1/122
OsteoporosisMusculoskeletal and connective tissue disorders1/122
Pain in ExtremityMusculoskeletal and connective tissue disorders1/122
Lower Respiratory Tract InfectionInfections and infestations1/122
Streptococcal BacteraemiaInfections and infestations1/122
Most frequent other events
Showing 10 of 86
Most frequent other events
EventRituximab 1000 mg
ContusionInjury, poisoning and procedural complications9/122
FatigueGeneral disorders7/122
HeadacheNervous system disorders7/122
NasopharyngitisInfections and infestations5/122
DiarrhoeaGastrointestinal disorders5/122
PetechiaeSkin and subcutaneous tissue disorders5/122
RashSkin and subcutaneous tissue disorders5/122
Upper respiratory tract infectionInfections and infestations4/122
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/122
Gingival bleedingGastrointestinal disorders3/122

Baseline characteristics

Safety population: all participants who received at least one dose of study medication and for whom follow-up safety information was available.

Age, Continuous
Age, Continuous(years)Rituximab
Mean49.5 ± 18.59
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female70
Male52
08

Study locations

12 sites
  • Adelaide, New South Wales 5011, Australia
  • Gosford, New South Wales 2250, Australia
  • Randwick, New South Wales NSW 2031, Australia
  • Sydney, New South Wales 2139, Australia
  • Sydney, New South Wales 2747, Australia
  • Westmead, New South Wales 2145, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5042, Australia
  • Frankston, Victoria 3199, Australia
  • Malvern, Victoria 3144, Australia
  • Melbourne, Victoria 3168, Australia
  • Parkville, Victoria 3052, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2007
First posted
May 21, 2007
Start
May 2007
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Feb 23, 2015
Last update
Feb 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00475423
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 21, 2007
Start date
May 2007
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Feb 23, 2015
Last update
Feb 23, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion